<address id="9ebc" ></address>
  • <option id="9ebc" ></option>

    1. <samp id="9ebc" ></samp>

    2. <p id="9ebc" ></p>
      1. <listing id="9ebc" ></listing><li id="9ebc" ><tt id="9ebc" ></tt></li>
        Log in
        Forgot password ?
        Become a member for free
        Sign up
        Sign up
        New member
        Sign up for FREE
        New customer
        Discover our services
        Dynamic quotes 



        SummaryAll NewsPress ReleasesOfficial PublicationsSector news单反相机镜头知识MarketScreener Strategies单反相机镜头知识Analyst Recommendations


        share with twitter share with LinkedIn share with facebook
        09/04/2020 | 03:20am EDT
        long trade
        Entry price : 单反相机镜头知识83.98€单反相机镜头知识 | Target : 单反相机镜头知识87.6€单反相机镜头知识 | Stop-loss : 单反相机镜头知识81.9€单反相机镜头知识 | Potential : 单反相机镜头知识4.31%单反相机镜头知识
        单反相机镜头知识After having been stuck in a trading range, shares in Sanofi are returning to the lower bound of the range phase. This appears to be a good opportunity for opening new positions.
        Investors have an opportunity to buy the stock and target the € 87.6.
        Sanofi : Sanofi : One could take advantage of the market's hesitation
        • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
        • The company has solid fundamentals for a short-term investment strategy.
        • Sanofi accounts for 4.40 % of our European Portfolio. A trade is currently open since 06/10/2020 with a purchase price of € 90.28. Discover the other 19 stocks of the European portfolio managed by the MarketScreener portfolio management team.

        • The share is getting closer to its long-term support in weekly data, at EUR 83.56, which offers good timing for buyers.
        • Graphically speaking, the timing seems perfect for purchasing the stock close to the EUR 82 support.
        • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
        • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
        • For the past twelve months, EPS forecast has been revised upwards.
        • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
        • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
        • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
        • The stock is in a well-established, long-term rising trend above the technical support level at 83.56 EUR

        • The group usually releases earnings worse than estimated.
        单反相机镜头知识Ratings chart单反相机镜头知识
        单反相机镜头知识Subsector Pharmaceuticals - NEC单反相机镜头知识
        1st jan.Capitalization (M$)Investor Rating
        SANOFI-6.75%123 842
        JOHNSON & JOHNSON1.86%391 211
        ROCHE HOLDING AG1.04%296 164
        MERCK & CO., INC.-6.28%215 593
        PFIZER, INC.-7.10%202 048
        NOVARTIS AG-14.28%189 551
        ABBVIE INC.3.76%162 135
        NOVO NORDISK A/S5.75%150 923
        AMGEN INC.3.04%145 486
        ASTRAZENECA PLC4.77%138 075
        ELI LILLY AND COMPANY14.82%136 795
        More Results

        share with twitter share with LinkedIn share with facebook

        Disclaimer: 单反相机镜头知识 The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
        The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

        Sales 2020 单反相机镜头知识36 898 M单反相机镜头知识 单反相机镜头知识43 683 M单反相机镜头知识 单反相机镜头知识43 683 M单反相机镜头知识
        Net income 2020 单反相机镜头知识11 711 M单反相机镜头知识 单反相机镜头知识13 865 M单反相机镜头知识 单反相机镜头知识13 865 M单反相机镜头知识
        Net Debt 2020 单反相机镜头知识7 852 M单反相机镜头知识 单反相机镜头知识9 296 M单反相机镜头知识 单反相机镜头知识9 296 M单反相机镜头知识
        P/E ratio 2020 单反相机镜头知识9,09x单反相机镜头知识
        Yield 2020 单反相机镜头知识3,82%单反相机镜头知识
        Capitalization 单反相机镜头知识105 B单反相机镜头知识 单反相机镜头知识124 B单反相机镜头知识 单反相机镜头知识124 B单反相机镜头知识
        EV / Sales 2020 单反相机镜头知识3,06x单反相机镜头知识
        EV / Sales 2021 单反相机镜头知识2,82x单反相机镜头知识
        Nbr of Employees 单反相机镜头知识100 409单反相机镜头知识
        Free-Float 单反相机镜头知识89,0%单反相机镜头知识
        单反相机镜头知识Upcoming event on SANOFI单反相机镜头知识
        单反相机镜头知识Income Statement Evolution单反相机镜头知识
        Mean consensus OUTPERFORM
        Number of Analysts 25
        Average target price 单反相机镜头知识 105,22 € 单反相机镜头知识
        Last Close Price 单反相机镜头知识 83,57 € 单反相机镜头知识
        Spread / Highest target 单反相机镜头知识47,0%单反相机镜头知识
        Spread / Average Target 单反相机镜头知识25,9%单反相机镜头知识
        Spread / Lowest Target 单反相机镜头知识1,71%单反相机镜头知识
        单反相机镜头知识EPS Revisions 单反相机镜头知识
        Paul Hudson Chief Executive Officer & Director
        Serge Weinberg Chairman
        Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
        John C. Reed EVP & Global Head-Research & Development
        Nestle Frank Global Head-Immunology Therapeutic Research Area